pbs_code
stringlengths 5
6
| drug
stringclasses 17
values | brand
stringclasses 30
values | formulation
stringclasses 37
values | indication
stringclasses 8
values | treatment_phase
stringclasses 57
values | streamlined_code
stringclasses 33
values | online_application
bool 2
classes | authority_method
stringclasses 2
values | hospital_type
stringclasses 3
values | schedule_code
int64 3.57k
3.57k
| schedule_year
int64 2.03k
2.03k
| schedule_month
stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
13731Q | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | Subsequent continuing treatment | 14485 | true | STREAMLINED | Private | 3,571 | 2,025 | FEBRUARY |
10056G | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
10056G | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
10056G | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
10056G | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
3448L | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | juvenile idiopathic arthritis | Continuing Treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
3448L | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | juvenile idiopathic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12086D | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment in a patient weighing less than 30 kg | 14084 | true | STREAMLINED | Any | 3,571 | 2,025 | FEBRUARY |
12766X | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
12435L | adalimumab | Amgevita | Injection 20 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
12435L | adalimumab | Amgevita | Injection 20 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
12435L | adalimumab | Amgevita | Injection 20 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
12435L | adalimumab | Amgevita | Injection 20 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
8779C | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
8779C | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12429E | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12429E | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12429E | adalimumab | Hyrimoz | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12429E | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12429E | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12429E | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12429E | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12429E | adalimumab | Hyrimoz | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12429E | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12429E | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12429E | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12429E | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12429E | adalimumab | Hyrimoz | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12429E | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12429E | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12429E | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12429E | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12429E | adalimumab | Hyrimoz | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12429E | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12429E | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12399N | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12399N | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12399N | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12399N | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12399N | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12399N | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12399N | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12399N | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12399N | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
11486M | infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Public | 3,571 | 2,025 | FEBRUARY |
11486M | infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Public | 3,571 | 2,025 | FEBRUARY |
11486M | infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Public | 3,571 | 2,025 | FEBRUARY |
11486M | infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Public | 3,571 | 2,025 | FEBRUARY |
13057F | infliximab | Remsima SC | Solution for injection 120 mg in 1 mL pre-filled syringe | ankylosing spondylitis | Initial treatment with the subcutaneous form where a concurrent PBS authority application for the intravenously (IV) administered formulation is being made | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
11730J | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Continuing Treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
11730J | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
10079L | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
10079L | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
10079L | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
10079L | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
12297F | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | non-radiographic axial spondyloarthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12297F | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | non-radiographic axial spondyloarthritis | Initial 1 (New patient), Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
10906B | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | ankylosing spondylitis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
10906B | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
13339C | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Continuing treatment | 14164 | true | STREAMLINED | Public | 3,571 | 2,025 | FEBRUARY |
9641K | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
9641K | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
9641K | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
9641K | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
12328W | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 3,571 | 2,025 | FEBRUARY |
12328W | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 3,571 | 2,025 | FEBRUARY |
12328W | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 3,571 | 2,025 | FEBRUARY |
12328W | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 3,571 | 2,025 | FEBRUARY |
12328W | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 3,571 | 2,025 | FEBRUARY |
12328W | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 3,571 | 2,025 | FEBRUARY |
12328W | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 3,571 | 2,025 | FEBRUARY |
12328W | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 3,571 | 2,025 | FEBRUARY |
13216N | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | psoriatic arthritis | Subsequent continuing treatment | 11523 | true | STREAMLINED | Any | 3,571 | 2,025 | FEBRUARY |
13216N | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled syringe | psoriatic arthritis | Subsequent continuing treatment | 11523 | true | STREAMLINED | Any | 3,571 | 2,025 | FEBRUARY |
13209F | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Subsequent continuing treatment | 11604 | true | STREAMLINED | Any | 3,571 | 2,025 | FEBRUARY |
13209F | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Subsequent continuing treatment | 11604 | true | STREAMLINED | Any | 3,571 | 2,025 | FEBRUARY |
11979L | upadacitinib | Rinvoq | Tablet 15 mg | rheumatoid arthritis | First Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
11979L | upadacitinib | Rinvoq | Tablet 15 mg | rheumatoid arthritis | First Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
13684F | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | Subsequent continuing treatment | 14621 | true | STREAMLINED | Public | 3,571 | 2,025 | FEBRUARY |
13730P | tofacitinib | Xeljanz | Tablet 5 mg | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 3,571 | 2,025 | FEBRUARY |
9034L | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9034L | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9034L | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9034L | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9034L | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9034L | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9034L | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9034L | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9034L | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9034L | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9034L | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9034L | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9455P | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9455P | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9455P | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9455P | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9455P | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9455P | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9455P | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9455P | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
End of preview. Expand
in Dataset Viewer.
README.md exists but content is empty.
- Downloads last month
- 90
Size of downloaded dataset files:
24 kB
Size of the auto-converted Parquet files:
24 kB
Number of rows:
1,664